The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Sanofi
Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.
 
Semini Sumanasuriya
No Relationships to Disclose
 
George Seed
No Relationships to Disclose
 
Niven Mehra
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Genzyme; Janssen-Cilag; MSD Oncology; Roche; Roche
Speakers' Bureau - Roche
Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Roche
 
Rossitza Christova
No Relationships to Disclose
 
Lorna Pope
No Relationships to Disclose
 
Jane Goodall
No Relationships to Disclose
 
Penelope Flohr
No Relationships to Disclose
 
Gemma Fowler
No Relationships to Disclose
 
Diletta Bianchini
Honoraria - Janssen
Travel, Accommodations, Expenses - Janssen
 
Pasquale Rescigno
No Relationships to Disclose
 
Suzanne Carreira
No Relationships to Disclose
 
Wei Yuan
Other Relationship - Yinghuahengrui
 
Sandrine Macé
Employment - Sanofi
 
Mustapha Chadjaa
No Relationships to Disclose
 
Johann S. De Bono
Honoraria - Astellas Pharma; AstraZeneca; BioExcel; Daiichi Sankyo; Genentech/Roche; Janssen Oncology; Menarini Silicon Biosystems; Pfizer; Sanofi; Sierra Oncology
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BioXCel therapeutics; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; Janssen Oncology; Menarini Silicon Biosystems; Merck Serono; Merck Sharp & Dohme; Orion; Pfizer; Sanofi; Sierra Oncology; Taiho Pharmaceutical
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); CellCentric (Inst); Daiichi Sankyo (Inst); Genentech (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Medivation (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Orion (Inst); Sanofi (Inst); Sierra Oncology (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); CHK1 inhibitor (Inst); PARP inhibitors and DNA repair defects (Inst); Targeting of IL23 in prostate cancer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex